Cross-sectional study
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US
- Serial cross-sectional study
- nationally representative sample (NHANES)
Authors' conclusion
In this study, statin use for primary prevention of ASCVD was low among all race and ethnicity groups regardless of ASCVD risk, with the lowest use occurring among Black and Hispanic adults.
Study context
- Population
- US adults aged 40 to 75 years without atherosclerotic cardiovascular disease (ASCVD), DM or LDL-C ≥190 mg/dL, NHANES 2013 to March 202039.4 million US adults weighted
- Participants
- 3,417 participants
- Exposure
- Primary prevention statin use by race and ethnicity and 10-year ASCVD risk
- Asiann = 329
- Blackn = 1,032
- Hispanicn = 786
- Whiten = 1,270reference
- Outcome
- Prevalence of statin use (statin identified on pill bottle review)
Main finding
As reported in the abstract
Statin use, overall cohort
Observational data: associations, not effects.
Further findings
| Outcome | Asian | Black | Hispanic | White | prevalence ratio (95% CI) | |
|---|---|---|---|---|---|---|
| Statin use in highest risk stratum (≥20%) — Black vs White | Not reported in the abstract | 23.8% | 23.9% | Not reported in the abstract | 0.90 (0.82–0.98) | |
| Statin use in highest risk stratum (≥20%) — Hispanic vs White | 0.90 (0.81–0.99) | |||||
| 0.512Prevalence ratio (log scale) |
Statin use across ASCVD risk strata and over time
- Graded increase in statin use across increasing ASCVD risk strata within each race and ethnicity group
- Routine health care access and health insurance significantly associated with higher statin use in Black, Hispanic and White adults
- Prevalence of statin use did not meaningfully change over time by race and ethnicity or ASCVD risk stratum
Original publication
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US. JAMA Cardiol. Published 1 May 2023. doi:10.1001/jamacardio.2023.0228
Summarised from the published abstract; every number is checked against it